Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Overcoming Multi-drug Resistence in Myeloma?
Overcoming Multi-drug Resistence in Myeloma?
Overcoming multidrug resistance in myeloma is too good to be true. I say this because every MM survivor knows what it feels like when whatever chemo regimen they are taking stops working, allowing their MM to grow again, causing a relapse.
In the video below, the oncologist explains how complicated MM is and, therefore, how many ways MM cells can become resistant to treatment.
Mechanisms of resistance in multiple myeloma treatments
But what would happen if MM cells could be treated with “tumor treating fields,” making them more open or susceptible to chemotherapy? A physical treatment eliminating MM resistance?
As a long-term MM survivor, I have to admit that I have wondered many times if oncology wasn’t overthinking MM treatment. TTF technology is a long way from your oncologist’s office. I will be following this technology as it moves through testing, trials, etc.
Scroll down the page and post comments or questions you may have about managing your MM.
Hang in there,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug Resistance
Abstract
Results
TTFields-induced cancer cell permeability is a pan-cancer phenomenon absent in noncancerous cells
The optimal frequency for the cytotoxic effects of TTFields varies according to cancer type (19), prompting evaluation of their effects on cellular permeability across multiple cancer cell lines over a relevant frequency range. Cellular permeability was assessed by measuring the uptake of the fluorescent exclusion dye 7-AAD, which cannot traverse intact plasma membranes of viable cells.
Cells were exposed to TTFields for 24 hours, and 7-AAD was added 15 minutes prior to the end of treatment. Maximal membrane permeability occurred at 300 kHz in mammary carcinoma (4T1), glioblastoma (U-87 MG), and Lewis lung carcinoma (LL/2) cells, whereas uterine sarcoma (MES-SA) and ovarian carcinoma (A2780) cells exhibited peak permeability at 150 kHz (Fig. 1A–E; Supplementary S1A–S1D).
These frequencies differed from those inducing maximal cytotoxicity [150 kHz for 4T1 (Supplementary Fig. S1E) and LL/2 (27), 200 kHz for U-87 MG (19) and A2780 (28), and 100 kHz for MES-SA cells (Supplementary Fig. S1F)]. Notably, noncancerous cells (lung fibroblasts, MRC-5; brain endothelial cells, HBMVEC) showed no increased permeability following TTFields exposure (Fig. 1F and G)…
In conclusion, our findings highlight important implications for incorporating TTFields into clinical strategies aiming to enhance the effectiveness of standard chemotherapeutics, particularly in cancers exhibiting MDR phenotypes. Future studies could explore exploiting TTFields-induced cancer cell permeability for use with small-molecule targeted therapies, such as PARP inhibitors…”
Overcoming multidrug resistance in myeloma Overcoming multidrug resistance in myeloma Overcoming multidrug resistance in myeloma